Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-11-05

FDA Approved: WELLBUTRIN SR — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for Wellbutrin SR, updating the labeling for the bupropion extended-release formulation following GlaxoSmithKline's subm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • WELLBUTRIN SR (BUPROPION HYDROCHLORIDE)

Snippet

SUPPL AP for WELLBUTRIN SR (BUPROPION HYDROCHLORIDE)